A precision immunology company targeting dendritic cell (DC)-driven autoimmune disease where most therapies act too late in the inflammatory cascade — starting with RA Wield Therapeutics operates in Life Science, Therapeutics; this dossier captures the Pre-Seed we participated in.
via StoryHouse Fund II, in a $1.2M round.
Update email from Patrick Collins: Hi Matthew & Keith, It was a pleasure to meet Matthew, Miles, Josh and Vidusshi yesterday afternoon in San Francisco. Since we last corresponded: • We generated dose response data for our lead panel in the receptor:ligand blocking assay and found that one clone has an IC50 within ~5pM of AMG329 (this clone als…
Source: Meeting Notes reccI9RIln5qfXiMv
NOTE: Granola notes below have some inaccuracies and overly simplistic summary comments. KH and MJE Zoom with Dr. Baker and discussion between KH and MJE before and after Zoom with Dr. Baker. Date: May 4, 2026 Dr. Matthew Baker’s Background & Expertise • Leading rheumatology expert at Stanford • Youngest department chair at Mass Gen (immunolo…
Source: Meeting Notes recoh83hAUdzH1urI
Wield / Zoom notes April 29 with Wield, Keith and Matthew Company Background & Team • Jennifer Low: Former CMO at Loxo Oncology (employee #9, helped take public, $8B Lilly acquisition), 30+ years clinical research, ex-23andMe drug development lead • Patrick Collins: Pomona '99, ex-Amgen 9 years (target ID, mechanism studies), ex-23andMe function…
Source: Meeting Notes recsxdXYQUjKLyQho